Nephroprotective and clinical potential of statins in dialyzed patients.
Expert Opin Ther Targets
; 13(5): 541-50, 2009 May.
Article
en En
| MEDLINE
| ID: mdl-19368496
BACKGROUND: The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD. OBJECTIVE: To examine the use of statins in CKD. METHODS: A review of relevant literature. RESULTS/CONCLUSION: Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diálisis Renal
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Fallo Renal Crónico
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Idioma:
En
Revista:
Expert Opin Ther Targets
Asunto de la revista:
TERAPEUTICA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Polonia
Pais de publicación:
Reino Unido